Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for Keros Therapeutics (KROS) over the last 3 years, with Q4 2021 value amounting to $12.1 million.

  • Keros Therapeutics' Total Non-Current Liabilities rose 5766.32% to $12.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $12.1 million, marking a year-over-year increase of 5766.32%. This contributed to the annual value of $12.1 million for FY2021, which is 5766.32% up from last year.
  • Per Keros Therapeutics' latest filing, its Total Non-Current Liabilities stood at $12.1 million for Q4 2021, which was up 5766.32% from $11.5 million recorded in Q3 2021.
  • Keros Therapeutics' 5-year Total Non-Current Liabilities high stood at $12.1 million for Q4 2021, and its period low was $7.4 million during Q3 2020.
  • For the 3-year period, Keros Therapeutics' Total Non-Current Liabilities averaged around $9.4 million, with its median value being $9.3 million (2021).
  • As far as peak fluctuations go, Keros Therapeutics' Total Non-Current Liabilities plummeted by 2592.59% in 2020, and later surged by 5766.32% in 2021.
  • Keros Therapeutics' Total Non-Current Liabilities (Quarter) stood at $10.3 million in 2019, then decreased by 25.93% to $7.7 million in 2020, then skyrocketed by 57.66% to $12.1 million in 2021.
  • Its Total Non-Current Liabilities stands at $12.1 million for Q4 2021, versus $11.5 million for Q3 2021 and $7.8 million for Q2 2021.